Literature DB >> 31700663

HIV-1 elite controllers: an immunovirological review and clinical perspectives.

Nour Y Gebara1, Vanessa El Kamari2, Nesrine Rizk1,3.   

Abstract

HIV type 1 (HIV-1) elite controllers (ECs) represent a rare group of individuals with an ability to maintain an undetectable HIV-1 viral load overtime in the absence of previous antiretroviral therapy. The mechanisms associated with this paradigm remain not clearly defined. However, loss of virological control, morbidity and mortality persist in these individuals, such as progress to AIDS-defining conditions together with persistent high rate of immune activation. Further insight into potential therapeutic options is therefore warranted. In this review, we discuss recent data on the type of immune responses understood to be associated with chronic virological control, the potential for disease progression and therapeutic options in ECs.
© 2019 The Authors. Journal of Virus Eradication published by Mediscript Ltd.

Entities:  

Year:  2019        PMID: 31700663

Source DB:  PubMed          Journal:  J Virus Erad        ISSN: 2055-6640


  14 in total

1.  Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review.

Authors:  Bridget Myers; Quinn Thibodeaux; Vidhatha Reddy; Stephanie Chan; Nicholas Brownstone; Wilson Liao; Tina Bhutani
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2020-09-16

2.  Approach to the management of paediatric HIV spontaneous controllers.

Authors:  Peter Zuidewind; Mark Cotton; Shaun Barnabas; Anita Janse Van Rensburg; Gert van Zyl; Carli Gordijn
Journal:  S Afr J Infect Dis       Date:  2022-06-30

Review 3.  Mechanism of Viral Suppression among HIV Elite Controllers and Long-Term Nonprogressors in Nigeria and South Africa.

Authors:  Rahaman Ademolu Ahmed; Khalid Olajide Adekoya; Chika Kingsley Onwuamah; Bolanle Olufunmilayo Oboh; Smita Swaminathan Iyer; Ayomide Samuel Oluwatosin; Rosemary Ajuma Audu; Oliver Chukwujekwu Ezechi
Journal:  Viruses       Date:  2022-06-10       Impact factor: 5.818

Review 4.  A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection.

Authors:  Samaa T Gobran; Petronela Ancuta; Naglaa H Shoukry
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561

Review 5.  So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.

Authors:  Adam J Kleinman; Ivona Pandrea; Cristian Apetrei
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

6.  Towards the next step: LoViRet patients for HIV-1 cure studies.

Authors:  Raquel Crespo; Casper Rokx; Tokameh Mahmoudi
Journal:  EBioMedicine       Date:  2020-07-20       Impact factor: 8.143

Review 7.  Dual Antiretroviral Therapy-All Quiet Beneath the Surface?

Authors:  Berend J van Welzen; Patrick G A Oomen; Andy I M Hoepelman
Journal:  Front Immunol       Date:  2021-02-12       Impact factor: 7.561

Review 8.  P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target.

Authors:  Silvere D Zaongo; Yanqiu Liu; Vijay Harypursat; Fangzhou Song; Huan Xia; Ping Ma; Yaokai Chen
Journal:  Front Immunol       Date:  2021-08-09       Impact factor: 7.561

Review 9.  How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika.

Authors:  Morgan E Abernathy; Kim-Marie A Dam; Shannon R Esswein; Claudia A Jette; Pamela J Bjorkman
Journal:  Viruses       Date:  2021-10-19       Impact factor: 5.818

10.  High Plasma sTNF-R1 Level Is Related to Loss of Natural HIV Control in Long-Term Elite Controllers.

Authors:  Daniel Sepúlveda-Crespo; Norma Rallón; María José Muñoz-Gómez; Oscar Brochado-Kith; José Luis Jiménez; María Ángeles Muñoz-Fernández; José M Benito; Salvador Resino
Journal:  Front Cell Infect Microbiol       Date:  2022-03-17       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.